Elite in Carcinoid Syndrome

Tahir S. Shah

Birmingham, ENG, GB 
Clinical Trials:Currently Recruiting for 1 Trial
Elite in Carcinoid Syndrome
Birmingham, ENG, GB 
OverviewLocationsClinical Research

Overview

Tahir Shah practices in Birmingham, United Kingdom. Mr. Shah is rated as an Elite expert by MediFind in the treatment of Carcinoid Syndrome. His top areas of expertise are Carcinoid Syndrome, Neuroendocrine Tumor, Liver Cancer, Liver Transplant, and Pancreaticoduodenectomy.

His clinical research consists of co-authoring 63 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 6 articles in the study of Carcinoid Syndrome.

Gender
Male

Locations

Birmingham, ENG, United Kingdom
Other Locations
London, ENG, United Kingdom
Edgbaston, ENG, United Kingdom
Bolton, ENG, United Kingdom
Hinxton, ENG CB101SA, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
Enrollment Status: Recruiting
Publish Date: May 01, 2025
Intervention Type: Genetic
A Multicenter, Open-label Post Authorization Safety Study to Evaluate the Effect of LysaKare® Infusion on Serum Potassium Levels in GEP-NET Patients Eligible for Lutathera® Treatment
A Multicenter, Open-label Post Authorization Safety Study to Evaluate the Effect of LysaKare® Infusion on Serum Potassium Levels in GEP-NET Patients Eligible for Lutathera® Treatment
Enrollment Status: Completed
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drug: LysaKare
Study Phase: Phase 4
A Phase II/III Randomized Double-blind Study of Sandostatin LAR in Combination With Axitinib Versus Sandostatin LAR With Placebo in Patients With Advanced G1-G2 Neuroendocrine Tumours (WHO 2010) of Non-pancreatic Origin
A Phase II/III Randomized Double-blind Study of Sandostatin LAR in Combination With Axitinib Versus Sandostatin LAR With Placebo in Patients With Advanced G1-G2 Neuroendocrine Tumours (WHO 2010) of Non-pancreatic Origin
Enrollment Status: Unknown
Publish Date: February 02, 2021
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
View 2 Less Clinical Trial

63 Total Publications

Toward Low-Emission Agriculture: Synergistic Contribution of Inorganic Nitrogen and Organic Fertilizers to GHG Emissions and Strategies for Mitigation.
Toward Low-Emission Agriculture: Synergistic Contribution of Inorganic Nitrogen and Organic Fertilizers to GHG Emissions and Strategies for Mitigation.
Journal: Plants (Basel, Switzerland)
Published: April 01, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Shah's expertise for a condition
ConditionClose
View All 11 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile